Khalid Abu Ajaj

582 total citations
16 papers, 497 citations indexed

About

Khalid Abu Ajaj is a scholar working on Biomaterials, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Khalid Abu Ajaj has authored 16 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Biomaterials, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Oncology. Recurrent topics in Khalid Abu Ajaj's work include Nanoparticle-Based Drug Delivery (8 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Khalid Abu Ajaj is often cited by papers focused on Nanoparticle-Based Drug Delivery (8 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Khalid Abu Ajaj collaborates with scholars based in Germany, Egypt and Saudi Arabia. Khalid Abu Ajaj's co-authors include Felix Kratz, André Warnecke, Ralph Graeser, Michael Bienert, Martin L. Biniossek, Iduna Fichtner, Hans‐Jürgen Laws, Gisa Gerold, Arturo Zychlinsky and Heike Nikolenko and has published in prestigious journals such as Nature Immunology, Cancer Research and Journal of Controlled Release.

In The Last Decade

Khalid Abu Ajaj

16 papers receiving 477 citations

Peers

Countries citing papers authored by Khalid Abu Ajaj

Since Specialization

Citations

This map shows the geographic impact of Khalid Abu Ajaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khalid Abu Ajaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khalid Abu Ajaj more than expected).

Fields of papers citing papers by Khalid Abu Ajaj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khalid Abu Ajaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khalid Abu Ajaj. The network helps show where Khalid Abu Ajaj may publish in the future.

Co-authorship network of co-authors of Khalid Abu Ajaj

This figure shows the co-authorship network connecting the top 25 collaborators of Khalid Abu Ajaj. A scholar is included among the top collaborators of Khalid Abu Ajaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khalid Abu Ajaj. Khalid Abu Ajaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound 2019 ·Journal of Controlled Release ·(unknown), (unknown), Johannes P. Magnusson, Serghei Chercheja, Federico Medda, Khalid Abu Ajaj, Didier Rognan, Steffen Daum, Friederike I. Nollmann, Javier García, (unknown), (unknown), (unknown), Felix Kratz	25
2	Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors 2019 ·Nuclear Medicine and Molecular Imaging ·Steffen Daum, Johannes P. Magnusson, (unknown), F. Fernandez, Serghei Chercheja, Federico Medda, Friederike I. Nollmann, (unknown), (unknown), André Warnecke, Khalid Abu Ajaj, Felix Kratz	8
3	Abstract 1657: Structure-activity relationship studies and biological evaluation of novel maytansinoids, a class of highly selective tubulin inhibitors 2018 ·Cancer Research ·Friederike I. Nollmann, (unknown), F. Fernandez, (unknown), Johannes P. Magnusson, Federico Medda, Felix Kratz, (unknown), Khalid Abu Ajaj, (unknown), Serghei Chercheja, (unknown)	1
4	Abstract 4858: LADR™: A novel linker activated drug release technology for drug delivery 2016 ·Cancer Research ·Khalid Abu Ajaj, (unknown), Friederike I. Nollmann, (unknown), (unknown), André Warnecke, Felix Kratz	1
5	Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin 2012 ·Breast Cancer Research and Treatment ·Khalid Abu Ajaj, Ralph Graeser, Felix Kratz	21
6	Development of Novel Bisphosphonate Prodrugs of Doxorubicin for Targeting Bone Metastases That Are Cleaved pH Dependently or by Cathepsin B: Synthesis, Cleavage Properties, and Binding Properties to Hydroxyapatite As Well As Bone Matrix 2012 ·Journal of Medicinal Chemistry ·(unknown), Khalid Abu Ajaj, (unknown), Felix Kratz	89
7	Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative 2011 ·European Journal of Cancer ·Khalid Abu Ajaj, (unknown), Pia Welker, Samar S. Azab, Reiner Zeisig, Iduna Fichtner, Felix Kratz	11
8	Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: An in vitro and in vivo evaluation study 2010 ·European Journal of Cancer ·Bakheet Elsadek, Ralph Graeser, N. Esser, (unknown), Khalid Abu Ajaj, Clemens Unger, André Warnecke, Tahia H. Saleem, Nagla T. El-Melegy, Hafez Madkor, Felix Kratz	39
9	In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP) 2010 ·Prostate Cancer and Prostatic Diseases ·Bakheet Elsadek, Ralph Graeser, N. Esser, (unknown), Chizuko Tsurumi, Khalid Abu Ajaj, André Warnecke, Clemens Unger, Tahia H. Saleem, Felix Kratz	13
10	In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B 2009 ·Cancer Chemotherapy and Pharmacology ·Khalid Abu Ajaj, Ralph Graeser, Iduna Fichtner, Felix Kratz	46
11	Development of Protein-Binding Bifunctional Linkers for a New Generation of Dual-Acting Prodrugs 2009 ·Bioconjugate Chemistry ·Khalid Abu Ajaj, Martin L. Biniossek, Felix Kratz	45
12	A Toll-like receptor 2–integrin β3 complex senses bacterial lipopeptides via vitronectin 2008 ·Nature Immunology ·Gisa Gerold, Khalid Abu Ajaj, Michael Bienert, Hans‐Jürgen Laws, Arturo Zychlinsky, (unknown)	75
13	Development of dual-acting prodrugs for circumventing multidrug resistance 2008 ·Bioorganic & Medicinal Chemistry Letters ·Khalid Abu Ajaj, Felix Kratz	17
14	Anticancer carrier-linked prodrugs in clinical trials 2007 ·Expert Opinion on Investigational Drugs ·Felix Kratz, Khalid Abu Ajaj, André Warnecke	67
15	Dipalmitoylation of a cellular uptake-mediating apolipoprotein E-derived peptide as a promising modification for stable anchorage in liposomal drug carriers 2006 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Ines Sauer, Heike Nikolenko, Sandro Keller, Khalid Abu Ajaj, Michael Bienert, Margitta Dathe	34
16	Synthesis of a complex disaccharide precursor of phosphonate analogues of the antibiotic moenomycin A12 2002 ·Tetrahedron ·Khalid Abu Ajaj, Lothar Hennig, Matthias Findeisen, Sabine Giesa, D. Müller, Peter Welzel	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact